$4.72
-3.7%Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Wall Street analysts project that KLRS stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 18.25, with estimates ranging from a low of 14.00 to a high of 23.00.
The consensus 1-year price target stands at 18.25, with estimates ranging from a low of 14.00 to a high of 23.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Wide estimate range reveals significant forecast uncertainty and potential volatility.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Moderate uncertainty in forecasts—typical for companies with evolving business models.
Generally favorable outlook with reasonable growth prospects and analyst support.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Significant contraction projected—major business challenges or industry disruption likely.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
During the last 12 months, insiders have purchased $7.35M and sold $13K worth of KLRS shares, resulting in $7.34M of net buying activity.
244.3K
1.18M
1.9K
12.87K
+1.2M
+$1.17M
479.8K
5.00M
0
0.00
+5.0M
+$5.00M
235.0K
1.17M
0
0.00
+1.2M
+$1.17M
0
0.00
0
0.00
+0
+$0
Akkaraju Srinivas
Director, 10 Percent Owner:
$6.18M
Gall Matthew
Officer: Chief Financial Officer
$1.17M
Hagen Brett R
Officer: Chief Accounting Officer
$13K
Strong bullish signal with $7.34M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
2 insider buyers vs. 1 sellers. More insiders buying than selling indicates positive sentiment.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
Continue your KLRS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.